Drug intelligence / Profile preview

aurixim

Development stage: Phase 1
Lead developer: Biointegrator
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Aurixim is a rituximab conjugate under development by BioIntegrator for the treatment of several B-cell lymphomas, including B-cell Non-Hodgkin lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, small lymphocytic lymphoma, and lymphoma of lien marginal zone cells. The drug is administered as an intravenous infusion. Its mechanism of action involves targeting CD20 on B-cells via the rituximab component[1]. Rituximab is a recombinant chimeric murine/human antibody directed against the CD20 antigen with potential antineoplastic activity[7]. Aurixim is currently in Phase I clinical trials for Waldenstrom macroglobulinemia[1].

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on aurixim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aurixim.

Explore the full profile